Attendee search 

Actinobac Biomed is conducting IND-enabling studies for their primary drug candidate, Leukothera®, a highly effective therapeutic for the treatment of hematological malignancies including B-cell lymphoma. Leukothera™ is a naturally derived biologic that specifically targets the subset of white blood cells (WBCs) expressing activated leukocyte function antigen-1 (LFA-1). Since LFA-1 is only present on WBCs and its activated form is uniquely expressed on cancerous and hyper-inflammatory WBCs, other cells and tissues are not affected, minimizing negative side effects.

Actinobac has exclusively licensed the patent portfolio established by Rutgers University covering the use of Leukothera® for the treatment of multiple medical conditions including cancer, autoimmune/inflammatory diseases, and HIV infection. The company has raised $960,855 since 2009 and is presently seeking funds to support the GMP production and formulation ($700,000) of their drug candidate. This high quality material will be used to complete preclinical research and development activities ($900k), stability and storage testing ($500k), the assembly and filing of regulatory documentation and an IND application ($1 million), and perform safety and preliminary efficacy clinical studies ($1.5 million). Actinobac is presently in discussions with a number of major pharmaceutical companies and investment groups to provide scientific support and financing for these activities.